XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) (FRA:4XT) said its German diagnostics development partner, 3a-diagnostics GmbH has announced that its point-of-care coronavirus (COVID-19) RT-PCR test system, known as Covid-ID Lab, has been approved by European regulators, meaning it is now registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
The bioscience accelerator said it is currently in discussions with various potential distribution and wholesale partners as well as potential licensees, with a sales launch in Europe targeted for April. XPhyto said it will provide further information and updates in due course.
WATCH: XPhyto Therapeutics partner receives ISO certification for Covid-19 PCR Test
"Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic," XPhyto chief executive Hugh Rogers said in a statement.
"Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings," he added.
Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. The test does not require prior RNA extraction as part of the sample preparation, which the company said reduces the risk of cross-contamination and minimizes the need for lab materials and trained personnel.
Contact the author at calum@proactiveinvestors.com
Follow him on Twitter @Cal_Proac